Newsletter | March 3, 2021

03.03.21 -- Strategies For Advancing Poorly Bioavailable Molecules

 
Science-Based Technology Selection Process For Bioavailability Enhancement
 

Careful selection of the right technology to enhance bioavailability and oral drug absorption is essential in development programs from initial preclinical phases to commercialization. Explore physicochemical and biological obstacles to bioavailability and a process based on a series of inputs including the target product profile, drug properties, extensive past project experiences, technology maps, and absorption modeling.

In Vitro Testing: Considerations For Methodology And Design
 

The industry needs enabling technologies for improving oral bioavailability and to continue developing an understanding of how to characterize and use in vitro data for supersaturating bioavailability-enhancing formulations. This presentation outlines strategies to address low bioavailability and the methodologies and selection processes for in vitro bioperformance tools as well as two case studies.

Novel Platform Enables Creation Of ASD Solid Dosage Forms With High Drug Loadings
 

The prevalence of active compounds with low aqueous solubility exceeds 70% in drug pipelines, preventing the development of many compounds as effective medicines. A novel formulation platform makes it possible to meet the requirements for a successful high-loading spray-dried amorphous solid dispersion (ASD) dosage form, reducing tablet mass by nearly half to meet patient needs.

Accelerated Development, Shortened Timelines With Lipid-Based Formulations
 

Lipid-based formulations (LBF) can be a helpful tool for pharmaceutical and biotech leaders evaluating more and more low-solubility molecules with a growing focus on rapid development. LBF technology advancements and formulation guidance tools can shorten timelines and increase the success rate in reaching the target product profile (TPP) in early development.

Reference Material